Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00185068 · ClinicalTrials.gov registry record · Phase 4

An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With Hypertension

A Phase 4 study of Hypertension, sponsored by Daiichi Sankyo.

Completed
Registry status
Phase 4
Development phase
110
Enrollment target
16
Study locations

NCT00185068: Completed Phase 4 study of Hypertension, sponsored by Daiichi Sankyo.

NCT00185068 is a Phase 4 study of Hypertension that has completed, run by Daiichi Sankyo. The registered enrollment target is 110 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (97% lower). The trial reports 16 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00185068, a Phase 4 study of Hypertension, has completed, sponsored by Daiichi Sankyo.

COMPLETED
Registry status
Phase 4
Development phase
110 participants
Enrollment target
16
Study locations

Study Summary

Effect of increasing doses of olmesartan medoxomil and olmesartan medoxomil/hydrochlorothiazide on blood pressure in patients with hypertension

Conditions Studied

Interventions

  • DRUG Olmesartan medoxomil
  • DRUG Hydrochlorothiazide
  • DRUG Olmesartan medoxomil/hydrochlorothiazide

Study Locations (16)

California

  • - Fort Lauderdale
  • - Long Beach
  • - Roseville
  • - Sacramento
  • - Santa Anna
  • - Tustin
  • - Westlake Village

Florida

  • - DeLand
  • - Pembroke Pines

Illinois

  • - Orland Park

Louisiana

  • - New Orleans

Maine

  • - Auburn

Nebraska

  • - Omaha

New York

  • - Buffalo

Oklahoma

  • - Oklahoma City

Trial Details

FieldValue
Enrollment Target 110 participants
Start Date 2004-03
Est. Completion 2004-10
Phase Phase 4
Daiichi Sankyo

236 total trials

What the finished NCT00185068 record still lists

NCT00185068 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 3 interventions - of which Olmesartan medoxomil is the first listed.

NCT00185068 lists 16 locations in 9 states (California, Florida, Illinois).

Frequently Asked Questions

What is clinical trial NCT00185068 about?

NCT00185068 is a clinical study titled "An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With Hypertension". Effect of increasing doses of olmesartan medoxomil and olmesartan medoxomil/hydrochlorothiazide on blood pressure in patients with hypertension

What is the current status of trial NCT00185068?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 110 participants. The study started on 2004-03. Estimated completion is 2004-10.

What conditions does trial NCT00185068 study?

This clinical trial studies the following conditions: Hypertension.

What interventions are being tested in trial NCT00185068?

The interventions under investigation include: Olmesartan medoxomil (DRUG), Hydrochlorothiazide (DRUG), Olmesartan medoxomil/hydrochlorothiazide (DRUG).

Who is sponsoring clinical trial NCT00185068?

This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00185068 being conducted?

This trial has 16 study locations across California, Florida, Illinois, Louisiana, Maine. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00185068's enrollment target sits among peer trials

110 280th of 470 higher than 188 of 470 other Hypertension trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01530373 · 110 participants · Phase 2

    Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients

  • NCT02379377 · 110 participants · Phase 1

    18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant

  • NCT02411773 · 110 participants · Phase 1

    Sympatholysis in Chronic Kidney Disease

  • NCT03190941 · 110 participants · Phase 1

    Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00185068, the US trial registry maintained by the National Library of Medicine. NCT00185068 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.